DNA RNA and Cells
17 January 2024
VRG Therapeutics announces successful in vivo efficacy results of their CAR-T project targeting glioblastoma17 January 2024
Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia12 January 2024
Indapta Therapeutics Announces First Patients Treated with IDP-023 Allogeneic Natural Killer (NK) Cell Therapy for Cancer9 January 2024
GC Cell’s Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI Platform6 January 2024
AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)5 January 2024
AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies4 January 2024
AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disease meets primary endpoint3 January 2024
Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis (OA)3 January 2024
Belief BioMed Successfully Completed Dosing of First Subject in the Registrational Clinical Trial for Hemophilia A2 January 2024
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies27 December 2023
Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension26 December 2023
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseasesNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports